Evidence map›Paper›PMID 34528758›Full record

ArticleImmunity, inflammation and disease2021

Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis.

Lina Lin, Weixia Nong, Bin Luo, Yingying Ge, Xia Zeng, Feng Li, Rong Fan, Qingmei Zhang, Xiaoxun Xie

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, inflammation and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lina LinDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, China.ORCID 0000-0002-5355-3835
Weixia NongDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, China.
Bin LuoDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, China.
Yingying GeDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, China.
Xia ZengDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, China.
Feng LiDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, China.
Rong FanDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Chinese Medicine University, Nanning, China.
Qingmei ZhangDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, China.
Xiaoxun XieDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, China.
Guangxi Medical University · CNGuangxi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCancer testis (CT) antigens are attractive targets for cancer immunotherapy because of their expression restriction and immunogenicity. The acrosin binding protein (ACRBP) is a member of CT antigens. This study aimed to evaluate ACRBP expression and immunogenicity in ovarian cancer (OC).

methodsThe expression level of ACRBP in OC tissues, normal ovarian tissues, and cell lines was detected via quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry. We determined the levels of ACRBP antigen and antibody in serum samples collected from patients with OC and healthy donors using enzyme-linked immunosorbent assays (ELISA), the level of ACRBP in cell-cultured medium was also tested.

resultsACRBP mRNA and protein expressions were upregulated in OC tissues relative to normal tissue, especially highly expressed in epithelial ovarian cancer (EOC). Moreover, ACRBP expression was significantly correlated with International Federation of Gynecology and Obstetrics (FIGO) stage and chemosensitivity. Serological analysis showed that anti-ACRBP antibody was detected in the sera of 16 of the 56 (28.5%) patients with OC but not in healthy donors. The area under the receiver operating characteristic curve for ACRBP antibody was 0.802 (95% confidence interval [CI]: 0.708-0.876), and the sensitivity and specificity for ACRBP antibody was 85.71% and 55.0%, respectively. Kaplan-Meier analysis revealed that the overall survival (OS) and disease-free survival (DFS) in OC patients with high ACRBP expression were significantly lower than those with low expression (p = 0.040, p = 0.021). However, ACRBP antibody level was not associated with prognosis.

conclusionACRBP expression was upregulated in OC tissues and induced humoral immune response in patients with OC, suggesting that ACRBP is a potential prognostic biomarker and a target of tumor immunotherapy for OC.

Indexed as

Ovarian NeoplasmsTestisBiomarkers, TumorCarcinoma, Ovarian EpithelialCarrier ProteinsHumansMalePrognosisBiomarkers, TumorCarrier ProteinsACRBPcancer-testis antigendiagnostic markerimmunotherapyovarian cancer

Identifiers

PMID34528758
PMCPMC8589352
OpenAlexW3200769655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.